Digital Health Global

OCTOBER 23, 2023

Believes Nymox Management and Board Must Be Held Accountable for Prolonged Underperformance and Egregious Governance Practices Urges Shareholders to Vote on the WHITE Proxy Card to Install New Leadership and a New Board at Upcoming Special Meeting CARSON CITY, Nev. & The Committee to Restore Nymox Shareholder Value, Inc.

Pharmaceuticals 88

Pharmaceuticals Leadership Life Science Digital Health 88

Digital Health Global

JULY 14, 2023

CEO Transition Foster is an experienced C-Suite executive with a broad background in the healthcare, medical device, and pharmaceutical industries. Before joining CurvaFix, Foster was president and CEO of Trice Medical, a leader in the field of minimally invasive orthopedic procedures. Formerly he was V.P.

Pharmaceuticals 88

Pharmaceuticals Leadership Digital Health Medical Technology 88

Lloyd Price

MARCH 16, 2024

In addition to these core areas, there will likely be discussions on specific sectors within healthcare, such as pharmaceuticals, medical management, and healthcare delivery models. This could include discussions on healthcare disparities and strategies for achieving better health outcomes for all.

Life Science 67

Life Science Pharmaceuticals healthcare technology Leadership 67

Healthcare IT Today

JANUARY 10, 2023

Onc.AI , a medical technology company developing a novel digital clinical management solution focused on immuno-oncology, announced today it has closed a $25 million Series A financing co-led by MassMutual and Action Potential Venture Capital (a GSK venture fund). About Onc.AI.

Medical Technology 73

Medical Technology Pharmaceuticals Leadership Health IT 73

Healthcare IT Today

NOVEMBER 15, 2022

Post-acquisition, the Wilco Source leadership will run the integrated Salesforce business providing solutions and services across CitiusTech’s and Wilco Source’s existing and new clients. Risk Evaluation and Mitigation Strategies (REMS) solutions for pharmaceutical companies (Salesforce Health Cloud). About CitiusTech.

Life Science 57

Life Science Pharmaceuticals healthcare technology Leadership 57

Digital Health Global

MARCH 16, 2023

Seamless Therapeutics has a first-mover position with its innovative platform capable of modifying the long held standard recombination technology into a universal gene editing tool with unprecedented specificity. Forbion invests in life sciences companies that are active in the (bio) pharmaceutical space.

Life Science 88

Life Science Pharmaceuticals BioTech Drug Development 88

Digital Health Global

FEBRUARY 5, 2024

To bolster this expansion, Vektor will increase clinical support and drive additional clinical studies to showcase the technology’s impact and inform future innovation as well as continue efforts to secure reimbursement. “At TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

Life Science 88

Life Science Pharmaceuticals Medical Technology BioTech 88